Camber Pharmaceuticals, Inc.

Camber Pharmaceuticals, Inc. Camber Pharmaceuticals is a fully integrated pharmaceutical company that maintains quality and
integrity in all its products from API to finished dosage.

Camber Pharmaceuticals is a fully integrated
pharmaceutical company that maintains quality and integrity in all its products from API manufacturing to finished dosage. We have been recognized as one of the fastest growing generic pharmaceutical companies in the US the past three years. Ever since its inception, Camber has shown a tradition of excellence and deep sense of commitment in developing c

ost effective processes to offer wide range of affordable drugs. Through its parent company, Hetero, Camber is building on the strengths of vertical integration in discovery research,process chemistry, API manufacturing, formulation development and commercialization. Research & Development is the foundation of Hetero’s philosophy of developing cost-effective, high quality and safe medicines to society. Hetero has a team of over 400 dedicated scientists working in the areas of Process, Analytical and Discovery Research.

Camber Pharmaceuticals is excited to announce the addition of Chlorpromazine HCl Injection, USP to its current portfolio...
06/19/2025

Camber Pharmaceuticals is excited to announce the addition of Chlorpromazine HCl Injection, USP to its current portfolio.

Chlorpromazine HCl Injection, USP are indicated for the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance.

Chlorpromazine HCl Injection, USP are available in:
* 25 mg/mL - 25 x 1 mL Single -dose vials
* 50 mg/2 mL (25 mg/mL) - 25 x 2 mL Single-dose vials

To find out more information on Chlorpromazine HCl Injection, USP, please visit: www.camberpharma.com/chlorpromazineinjection

https://conta.cc/4n8zqU7

Email from Camber Pharmaceuticals View as Webpage Camber Launches Chlorpromazine HCl Injection, USP Piscataway, NJ, June 19, 2025 –Camber Pharmaceuticals is excited to announce the addition of Chlorpr

Camber announces the launch of Mycophenolate Mofetil Tablets, USP (generic for CellCept®), further expanding its immunos...
06/16/2025

Camber announces the launch of Mycophenolate Mofetil Tablets, USP (generic for CellCept®), further expanding its immunosuppressant portfolio following the April 2025 launch of Mycophenolate Mofetil Capsules. With over 48,000 organ transplants performed annually in the U.S.—and more than 100,000 patients still on waiting lists—Camber remains committed to providing critical therapies that support long-term organ acceptance and improve transplant outcomes.

Mycophenolate Mofetil Tablets, USP are an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants.

Mycophenolate Mofetil Tablets, USP are available in 500 mg strength, packaged in bottles of 100 and 500 tablets.

To find out more information on Mycophenolate Mofetil Tablets, USP, please visit: www.camberpharma.com/mycophenolatetablets

https://conta.cc/406rKaY

Email from Camber Pharmaceuticals View as Webpage Camber Launches Mycophenolate Mofetil Tablets, USP Piscataway, NJ, June 16, 2025 – Camber announces the launch of Mycophenolate Mofetil Tablets, USP (

Camber Pharmaceuticals is excited to announce the addition of Temozolomide Capsules, USP to the portfolio.Temozolomide C...
05/15/2025

Camber Pharmaceuticals is excited to announce the addition of Temozolomide Capsules, USP to the portfolio.

Temozolomide Capsules, USP is an alkylating drug indicated for the treatment of adults with:

Newly diagnosed glioblastoma concomitantly with radiotherapy and then as maintenance treatment
Anaplastic astrocytoma
Adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma
Treatment of adults with refractory anaplastic astrocytoma

Temozolomide Capsules, USP are available in the following strengths and sizes:

5 mg- 5 and 14 count
20 mg- 5 and 14 count
100 mg- 5 and 14 count
140 mg- 5 and 14 count
180 mg- 5 and 14 count
250 mg- 5 count

To find out more information on Temozolomide Capsules, USP, please visit: www.camberpharma.com/temozolomide

https://conta.cc/3Fa996K

Email from Camber Pharmaceuticals View as Webpage Camber Launches Temozolomide Capsules, USP Piscataway, NJ, May 15, 2025 –Camber Pharmaceuticals is excited to announce the addition of Temozolomide Ca

Camber Pharmaceuticals is excited to announce the addition of Eslicarbazepine Acetate Tablets to its portfolio.Eslicarba...
05/06/2025

Camber Pharmaceuticals is excited to announce the addition of Eslicarbazepine Acetate Tablets to its portfolio.

Eslicarbazepine Acetate Tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older.

Eslicarbazepine Acetate Tablets are available in:

200 mg, 400 mg, and 800 mg strengths in 30-count bottles
600 mg strength in a 60-count bottle

To find out more information on Eslicarbazepine Acetate Tablets, please visit: www.camberpharma.com/eslicarbazepine

https://conta.cc/4iMxeOM

Email from Camber Pharmaceuticals View as Webpage Camber Launches Eslicarbazepine Acetate Tablets Piscataway, NJ, May 6, 2025 –Camber Pharmaceuticals is excited to announce the addition of Eslicarbaze

Camber Pharmaceuticals is excited to announce the addition of Chlorzoxazone Tablets, USP.Chlorzoxazone Tablets, USP are ...
05/01/2025

Camber Pharmaceuticals is excited to announce the addition of Chlorzoxazone Tablets, USP.

Chlorzoxazone Tablets, USP are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.

Chlorzoxazone 250 mg Tablets, USP are available in 60 count bottles.

To find out more information on Chlorzoxazone Tablets, USP, please visit: www.camberpharma.com/chlorzoxazone
https://conta.cc/4lXuMI6

Email from Camber Pharmaceuticals View as Webpage Camber Launches Chlorzoxazone Tablets, USP Piscataway, NJ, April 29, 2025 –Camber Pharmaceuticals is excited to announce the addition of Chlorzoxazone

Camber Pharmaceuticals is excited to announce the addition of Phenylephrine Hydrochloride Injection, USP to their portfo...
05/01/2025

Camber Pharmaceuticals is excited to announce the addition of Phenylephrine Hydrochloride Injection, USP to their portfolio.

Phenylephrine Hydrochloride Injection, USP is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.

Phenylephrine Hydrochloride Injection, USP are available in:

10 mg/mL | 25 x 1 mL Single-Dose Vials
50 mg/5 mL (10 mg/mL) | 10 x 5 mL Vials
100 mg/10 mL (10 mg/mL) | 10 mL Vial

To find out more information on Phenylephrine Injection, USP , please visit: www.camberpharma.com/phenylephrine

https://conta.cc/3GBB93v

Email from Camber Pharmaceuticals View as Webpage Camber Launches Phenylephrine Hydrochloride Injection, USP Piscataway, NJ, May 1, 2025 –Camber Pharmaceuticals is excited to announce the addition of

Camber Pharmaceuticals is excited to announce the addition of Lurasidone Hydrochloride Tablets. Lurasidone Hydrochloride...
04/11/2025

Camber Pharmaceuticals is excited to announce the addition of Lurasidone Hydrochloride Tablets.

Lurasidone Hydrochloride Tablets are an atypical antipsychotic indicated for the treatment of:
· Schizophrenia in adults and adolescents (13 to 17 years)
· Depressive episode associated with Bipolar I Disorder (bipolar depression) in adults and pediatric patients (10 to 17 years) as monotherapy
· Depressive episode associated with Bipolar I Disorder (bipolar depression) in adults as adjunctive therapy with lithium or valproate

Lurasidone Hydrochloride Tablets in 20 mg, 40 mg, 60 mg, 80 mg, 120 mg strengths are available in 30 count bottles.

To find out more information on Lurasidone Hydrochloride Tablets, please visit: www.camberpharma.com/lurasidone

https://conta.cc/4i9kj9d

Email from Camber Pharmaceuticals View as Webpage Camber Launches Lurasidone Hydrochloride Tablets Piscataway, NJ, April 11, 2025 –Camber Pharmaceuticals is excited to announce the addition of Lurasid

Camber Pharmaceuticals is excited to announce the addition of Mycophenolate Mofetil Capsules, USP to their portfolio. My...
04/09/2025

Camber Pharmaceuticals is excited to announce the addition of Mycophenolate Mofetil Capsules, USP to their portfolio.

Mycophenolate Mofetil Capsules, USP are indicated for the prophylaxis of organ rejection, in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants.

Mycophenolate Mofetil Capsules, USP 250 mg are available in 100 and 500 count bottles.

To find out more information on Mycophenolate Mofetil Capsules, USP, please visit: www.camberpharma.com/mycophenolatecapsules

https://conta.cc/3FZISbg

Email from Camber Pharmaceuticals View as Webpage Camber Launches Mycophenolate Mofetil Capsules Piscataway, NJ, April 9, 2025 – Camber Pharmaceuticals is excited to announce the addition of Mycopheno

Camber Pharmaceuticals is excited to announce the addition of Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Or...
04/03/2025

Camber Pharmaceuticals is excited to announce the addition of Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution.

Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adult patients.

Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution 17.5 g/3.13g/1.6g is available in a carton of (2) - 6 ounce bottles.

To find out more information on Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution, please visit: www.camberpharma.com/sodiumpotassiummagnesium

https://conta.cc/43WqZV1

Camber Pharmaceuticals is excited to announce the addition of Sirolimus Oral Solution.Sirolimus Oral Solution is an mTOR...
01/29/2025

Camber Pharmaceuticals is excited to announce the addition of Sirolimus Oral Solution.

Sirolimus Oral Solution is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in patients aged greater or equal to 13 years, receiving renal transplants.

* Patients at low to moderate immunologic risk: use initially with cyclosporine (CsA) and corticosteroids. CsA withdrawal is recommended 2 to 4 months after transplantation.
* Patients at high immunologic risk: use in combination with CsA and corticosteroids

Sirolimus Oral Solution 1 mg/mL is now available in a 60 mL bottle.

To find out more information on Sirolimus Oral Solution, please visit: www.camberpharma.com/sirolimus

https://conta.cc/3PTtejk

Email from Camber Pharmaceuticals, Inc. New Product Launch View as Webpage Camber Launches Sirolimus Oral Solution Piscataway, NJ, January 29, 2025 –Camber Pharmaceuticals is excited to announce the a

01/10/2025

Camber Pharmaceuticals is excited to announce the addition of Nimodipine Oral Solution.

Nimodipine Oral Solution is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition.

Nimodipine Oral Solution 60 mg/20 mL (3 mg/mL) is available and packaged in a 16-ounce bottle.

To find out more information on Nimodipine Oral Solution, please visit: www.camberpharma.com/nimodipine

https://conta.cc/40rrnbz

Camber Pharmaceuticals is excited to announce the addition of Bortezomib for Injection. Bortezomib for Injection is a pr...
01/07/2025

Camber Pharmaceuticals is excited to announce the addition of Bortezomib for Injection.

Bortezomib for Injection is a proteasome inhibitor indicated for:
1. treatment of adult patients with multiple myeloma
2. treatment of adult patients with mantle cell lymphoma

Bortezomib for Injection is available in 3.5 mg strength, packaged in a single-dose vial.

To find out more information on Bortezomib for Injection please visit: www.camberpharma.com/bortezomib

https://conta.cc/3DLWGVM

Email from Camber Pharmaceuticals, Inc. New Product Launch View as Webpage Camber Launches Generic Velcade® Piscataway, NJ, January 7, 2024 –Camber Pharmaceuticals is excited to announce the addition

Address

Piscataway, NJ

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Website

Alerts

Be the first to know and let us send you an email when Camber Pharmaceuticals, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Our Story

Camber Pharmaceuticals is a fully integrated pharmaceutical company that maintains quality and integrity in all its products from API manufacturing to finished dosage. We have been recognized as one of the fastest growing generic pharmaceutical companies in the US the past three years. Ever since its inception, Camber has shown a tradition of excellence and deep sense of commitment in developing cost effective processes to offer wide range of affordable drugs. Through its parent company, Hetero, Camber is building on the strengths of vertical integration in discovery research,process chemistry, API manufacturing, formulation development and commercialization. Research & Development is the foundation of Hetero’s philosophy of developing cost-effective, high quality and safe medicines to society. Hetero has a team of over 400 dedicated scientists working in the areas of Process, Analytical and Discovery Research.